Proactive Dx

Developer of a point-of-care inflammatory biomarker platform that provides rapid, lab-comparable cytokine and inflammation marker measurements from a finger-prick sample.

Biotechnology
Active
Thousand Oaks, United States Founded 2025
Website ↗
Last updated 2026-08-22
Total raised
Stage
Founded
2025
Headcount
HQ
Thousand Oaks, United States
Sector
Biotechnology

About

Proactive Dx develops Q-SENS, a waveguide-based, capillary-blood platform that brings central-lab immunoassays to the home. Their research spans rapid microfluidics, silicon waveguide optics, and AI analytics to quantify virtually any protein biomarker—up to 32 in parallel—including cytokines, cardiac & metabolic markers, infectious antigens, and aging signatures, in less than 10 minutes. They focus on longitudinal immune profiling and resilience scoring for preventative, precision healthcare. The company was formed with a new founding team to build on and advance the Q-SENS technology originally developed at Proactive Diagnostics, and acquired all assets and IP from Proactive Diagnostics.

Q&A

What is Proactive Dx's primary focus?
Proactive Dx focuses on developing a point-of-care inflammatory biomarker platform that provides rapid, lab-comparable cytokine and inflammation marker measurements from a finger-prick sample.
What is the name of Proactive Dx's core technology platform?
Proactive Dx's core technology platform is called Q-SENS, a waveguide-based, capillary-blood platform designed to bring central-lab immunoassays to the home.
What technologies does Proactive Dx utilize in its platform?
Proactive Dx's Q-SENS platform incorporates rapid microfluidics, silicon waveguide optics, and AI analytics to quantify protein biomarkers.
When was Proactive Dx founded?
Proactive Dx was founded in 2025.
Who are the co-founders of Proactive Dx?
The co-founders of Proactive Dx are Dylan Brownstein, CEO & Co-Founder, and Reuven Duer, CSO & Co-Founder.
What is Proactive Dx's primary sector?
Proactive Dx's primary sector is Biotechnology.
What types of biomarkers can Proactive Dx's platform quantify?
Proactive Dx's platform can quantify various protein biomarkers, including cytokines, cardiac & metabolic markers, infectious antigens, and aging signatures.
What is the company's approach to healthcare?
Proactive Dx focuses on longitudinal immune profiling and resilience scoring for preventative, precision healthcare.

Team · 2

Dylan Brownstein
Founder · CEO & Co-Founder
LinkedIn ↗
Reuven Duer
Founder · CSO & Co-Founder

Sectors & technology

Primary sector
Biotechnology
Technologies
Target customers
Business model
B2B
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitepro-dx.com

Identifiers & details

Founded2025